Correlation Between Midsona AB and Enorama Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Midsona AB and Enorama Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Midsona AB and Enorama Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Midsona AB and Enorama Pharma AB, you can compare the effects of market volatilities on Midsona AB and Enorama Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Midsona AB with a short position of Enorama Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Midsona AB and Enorama Pharma.

Diversification Opportunities for Midsona AB and Enorama Pharma

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Midsona and Enorama is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Midsona AB and Enorama Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enorama Pharma AB and Midsona AB is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Midsona AB are associated (or correlated) with Enorama Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enorama Pharma AB has no effect on the direction of Midsona AB i.e., Midsona AB and Enorama Pharma go up and down completely randomly.

Pair Corralation between Midsona AB and Enorama Pharma

Assuming the 90 days trading horizon Midsona AB is expected to under-perform the Enorama Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Midsona AB is 1.5 times less risky than Enorama Pharma. The stock trades about -0.14 of its potential returns per unit of risk. The Enorama Pharma AB is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  396.00  in Enorama Pharma AB on August 25, 2024 and sell it today you would lose (19.00) from holding Enorama Pharma AB or give up 4.8% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Midsona AB  vs.  Enorama Pharma AB

 Performance 
       Timeline  
Midsona AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Midsona AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Enorama Pharma AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enorama Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Midsona AB and Enorama Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Midsona AB and Enorama Pharma

The main advantage of trading using opposite Midsona AB and Enorama Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Midsona AB position performs unexpectedly, Enorama Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enorama Pharma will offset losses from the drop in Enorama Pharma's long position.
The idea behind Midsona AB and Enorama Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes